Table 1. Baseline characteristics of the Mongolian and Western cohorts.

	Mongolian Cohort (n=192)	Western Cohort (n=187)	p value
Age (years)	61 (18-80)	66 (29-91)	<0.001
< 60 years (n, %)	82 (44.6)	32 (18.6)	<0.001
< 50 years (n, %)	20 (10.9)	7 (4.1)	0.017
Gender (male, %)	98 (53.6)	137 (79.7)	<0.001
Etiology HBV+ (n, %)	15 (7.8)	41 (21.9)	<0.001
HBV/HDV+ (n, %)	77 (40.1)	3 (1.6)
HBV/HCV/HDV+ (n, %)	12 (6.3)	0 (0)
HCV+ (n, %)	57 (29.7)	69 (36.9)
HBV/HCV (n, %)	2 (1)	0 (0)
Non-infected (n, %)	29 (15)	74 (39.6)
Bilirubin (mg/dL)	0.6 (0.1-3.7)	0.9 (0.3-3.8)	<0.001
Albumin (g/L)	41 (29-49)	40 (22-54)	ns
Platelets (109/L)	181 (76-574)	160 (27-493)	<0.001
< 150x109/L (n, %)	50 (28.6)	81 (47.4)	<0.001
AFP (IU/mL)	22 (1-121000)	12 (1-311190)	ns
> 400 IU/mL (n, %)	32 (20.9)	26 (16.4)	ns
Tumor size	5 (0.8-20)	4.2 (1-20)	0.001
> 5 cm (n, %)	93 (52.8)	67 (41.4)	0.039
BCLC stage (0-A, %)	132 (78.1)	129 (79.6)	ns
Multinodular disease (n, %)	26 (15.4)	42 (25.8)	0.021
Advanced liver fibrosis (F3-4, %)	64 (38.1)	106 (78.5)	<0.001
Cirrhosis (F4, %)	27 (16.1)	81 (60)	<0.001
Microvascular invasion (yes, %)	72 (47.7)	80 (46.5)	ns
Tumor grade (G3-4, %)	11 (10.6)	41 (28.7)	<0.001

HBV, hepatitis B virus; HCV, hepatitis C virus; HDV, hepatitis delta virus; AFP, alfa-fetoprotein; BCLC, Barcelona Clinic Liver Cancer The following variables have missing values for the Mongolian and Western cohorts, respectively: Age: 8 and 15 patients. Gender: 9 and 15 patients. Bilirubin, albumin, and platelets: 19 and 17 patients. AFP: 39 and 28 patients. Tumor size: 16 and 25 patients. BCLC stage: 23 and 25 patients. Tumor number: 23 and 24 patients. Liver fibrosis in 24 and 52 patients. Microvascular invasion in 41 and 15 patients. Tumor grade in 88 and 44 patients.